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Abstract
Background: Glycosylphosphatidylinositol biosynthesis defects (GPIBDs) cause a group of phenotypically overlapping
recessive syndromes with intellectual disability, for which pathogenic mutations have been described in 16 genes of
the corresponding molecular pathway. An elevated serum activity of alkaline phosphatase (AP), a GPI-linked enzyme,
has been used to assign GPIBDs to the phenotypic series of hyperphosphatasia with mental retardation syndrome
(HPMRS) and to distinguish them from another subset of GPIBDs, termed multiple congenital anomalies hypotonia
seizures syndrome (MCAHS). However, the increasing number of individuals with a GPIBD shows that hyperphosphatasia
is a variable feature that is not ideal for a clinical classification.
Methods: We studied the discriminatory power of multiple GPI-linked substrates that were assessed by flow cytometry
in blood cells and fibroblasts of 39 and 14 individuals with a GPIBD, respectively. On the phenotypic level, we evaluated
the frequency of occurrence of clinical symptoms and analyzed the performance of computer-assisted image analysis of
the facial gestalt in 91 individuals.
Results: We found that certain malformations such as Morbus Hirschsprung and diaphragmatic defects are more likely
to be associated with particular gene defects (PIGV, PGAP3, PIGN). However, especially at the severe end of the clinical
spectrum of HPMRS, there is a high phenotypic overlap with MCAHS. Elevation of AP has also been documented
in some of the individuals with MCAHS, namely those with PIGA mutations. Although the impairment of GPI-linked
substrates is supposed to play the key role in the pathophysiology of GPIBDs, we could not observe gene-specific profiles
for flow cytometric markers or a correlation between their cell surface levels and the severity of the phenotype. In contrast,
it was facial recognition software that achieved the highest accuracy in predicting the disease-causing gene in a GPIBD.
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Conclusions: Due to the overlapping clinical spectrum of both HPMRS and MCAHS in the majority of affected individuals,
the elevation of AP and the reduced surface levels of GPI-linked markers in both groups, a common classification as GPIBDs
is recommended. The effectiveness of computer-assisted gestalt analysis for the correct gene inference in a GPIBD and
probably beyond is remarkable and illustrates how the information contained in human faces is pivotal in the
delineation of genetic entities.
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Background
Inherited deficiencies of glycosylphosphatidylinositol
(GPI) biosynthesis are a heterogeneous group of recessive
Mendelian disorders that all share a common feature: the
function of GPI-linked proteins is compromised due to a
defect in GPI anchor synthesis or modification. Most of
the enzymes involved in this molecular pathway are
known and the biochemical steps are well described [1].
With respect to the effect of genetic mutations on the an-
chor and the GPI-linked substrate, several subdivisions of
the pathway have been in use: 1) early GPI anchor
synthesis, 2) late GPI anchor synthesis, 3) GPI transami-
dase, and 4) remodeling of fatty acids of the GPI anchor
after attachment to proteins (Additional file 1: Figure S1).
The last two groups are defined by their molecular ac-
tions and comprise the genes GPAA1, PIGK, PIGU,
PIGS, and PIGT for the GPI-transamidase and PGAP1,
PGAP2, PGAP3, MPPE1, and TMEM8 for fatty acid
remodeling. The differentiation between early and late
GPI anchor synthesis considers the molecular conse-
quence of the glycosylphosphatidylinositol biosynthesis
defect (GPIBD), which was suggested after an important
finding from Murakami et al. [2] regarding the release of
alkaline phosphatase (AP), a GPI anchor marker: if an-
chor synthesis is stuck at an earlier step, the transami-
dase is not activated and the hydrophobic signal peptide
of GPI anchor substrates is not cleaved. As soon as the
first mannose residue on the GPI anchor has been added
by PIGM, the transamidase tries to attach the substrate
to the anchor. However, if subsequent steps are missing,
the GPI anchored proteins (GPI-APs) might be less
stable and hyperphosphatasia was hypothesized to be a
consequence thereof.
The activity of the AP was regarded as such a discrimin-
atory feature that it resulted in the phenotypic series of
hyperphosphatasia with mental retardation syndrome
(HPMRS) 1 to 6, currently comprising the six genes
PGAP2, PGAP3, PIGV, PIGO, PIGW, and PIGY [3–9].
Whenever a pathogenic mutation was discovered in a new
gene of the GPI pathway and the developmentally delayed
individuals showed elevated AP in the serum, the gene was
simply added to this phenotypic series. If hyperphosphata-
sia was missing, the gene was linked to another phenotypic
series, multiple congenital anomalies hypotonia seizures
(MCAHS), that currently consists of PIGA, PIGN, and
PIGT [10–12]. However, the convention of dividing newly
discovered GPIBDs over these two phenotypic subgroups is
only reasonable if they really represent distinguishable
entities. This practice is now challenged by a growing num-
ber of exceptions. The expressivity of most features is vari-
able and even the AP seems to be a biomarker with some
variability: some individuals with mutations in PIGA also
show elevated AP levels [10, 13–15], and some individuals
with mutations in PIGO, PIGW, PGAP2, and PGAP3 show
AP levels that are only borderline high [16–20].
Recently, deleterious mutations were identified in PIGC,
PIGP, and PIGG in individuals with intellectual disability
(ID), seizures, and muscular hypotonia, but other features
considered to be a prerequisite for MCAHS or HPMRS
were missing [21–23]. Despite the large phenotypic over-
lap with most GPIBDs, a flow cytometric analysis of gran-
ulocytes in individuals with PIGG mutations did not show
reduced surface levels for GPI-APs [21–23]. However,
Zhao et al. [24] showed that an impairment of PIGG in fi-
broblasts affects the marker expression, indicating that
there might also be variability depending on the tissue. In
concordance with these finding, a case report of an indi-
vidual with ID and seizures that has mutations in PIGQ
seems suggestive of a GPIBD in spite of negative FACS
results [25].
The work of Makrythanasis et al. [23] can also be con-
sidered as a turning point in the naming convention of
phenotypes that are caused by deficiencies of the molecu-
lar pathway as OMIM has now started referring to them
as GPIBDs (see OMIM entry #610293 for a discussion). In
this work we go one step further in this direction and ask
whether the phenotypic series MCAHS and HPMRS
should also be abandoned in favor of a more gene-
centered description of the phenotype, which would also
be in accordance with what Jaeken [26] already suggested
for other congenital disorders of glycosylation. Referring
to GPIBD phenotypes in a gene-specific manner makes
particular sense if the gene can be predicted from the
phenotypic level with some accuracy. For this purpose, we
systematically analyzed the discriminatory power for
GPIBDs for previously reported individuals as well as 23
novel cases that were identified through routine diagnos-
tics. This also adds novel FACS results for 16 patients
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(blood or fibroblasts) as well as 19 novel mutations
(Additional file 1: Figure S2).
Apart from founder effects that explain the reoccurrence
of certain mutations at higher frequency, pathogenic muta-
tions have now been reported in many exons (Additional
file 1: Figure S2). However, not much is known about
genotype–phenotype correlations in these genes, which
makes bioinformatics interpretation of novel variants chal-
lenging. The phenotypic analysis, for which we received
ethics approval from the Charité University and obtained
informed consent from the responsible persons on behalf
of all study participants, is based on three different data
sources: 1) a comprehensive clinical description of the
phenotypic features in human phenotype ontology termin-
ology [27]; 2) flow cytometric profiles of multiple GPI-
linked markers; and 3) computer-assisted pattern
recognition on frontal photos of individuals with a molecu-
larly confirmed diagnosis.
The rationale behind flow cytometry and image analyses
is that GPIBDs might differ in their effect on GPI-APs and
their trafficking pathways, resulting in distinguishable phe-
notypes. Interestingly, we found that the facial gestalt was
well suited for delineating the molecular entity. The high
information content of facies has become accessible
recently through advanced phenotypic tools that might
also be used for the analysis of other pathway disorders.
Before we present the flow cytometry and automated
image analysis results we review the most important
phenotypic features of GPIBDs in the old schema of
phenotypic series HPMRS and MCAHS.
Methods
Clinical overview of HPMRS
HPMRS, which is also sometimes referred to as Mabry
syndrome (HPMRS1-6: MIM 239300, MIM 614749, MIM
614207, MIM 615716, MIM 616025, MIM 616809), can
present as an apparently non-syndromic form of ID at one
end of the clinical spectrum but also as a multiple con-
genital malformation syndrome at the other end (Table 1).
The distinct pattern of facial anomalies of Mabry
syndrome consist of wide set eyes, often with a large ap-
pearance and upslanting palpebral fissures, a short nose
with a broad nasal bridge and tip, and a tented upper lip.
The results of a computer-assisted comparison of the
gene-specific facial gestalt is given in the “Comparison of
the facial gestalt of GPIBDs” section.
Psychomotor delay, ID, and variable AP elevation are
the only consistent features of all individuals with patho-
genic mutations in PIGV [9, 28–34], PIGO [7, 16, 17, 31,
35–37], PGAP2 [4, 8, 18, 38], PGAP3 [5, 19, 39–41], and
PIGY [6]. Speech development, especially expressive lan-
guage, is more severely affected than motor skills in the
majority of the affected individuals (Table 1). Absent
speech development was observed in more than half of
the affected individuals. Speech difficulties may be com-
plicated by hearing loss, which is present in a minority
of affected individuals. In the different genetic groups,
seizures of various types and onset are present in about
65% of affected individuals. Most affected individuals
show a good response to anticonvulsive drugs, but a few
affected individuals are classified as drug resistant and
represent the clinically severe cases (individual 14-0585).
Muscular hypotonia is common in all types of HPMRS
(about 85%). Behavioral problems, in particular sleep
disturbances and autistic features, tend to be frequent
(81%) in affected individuals with PGAP3 mutations and
are described in a few affected individuals with PIGY
mutations but are not documented in affected individ-
uals with mutations in the other four genes. Further-
more, ataxia and unsteady gait have been documented in
almost half of the affected individuals carrying PGAP3
mutations and about a third of this group did not
achieve free walking at all.
Elevated values of AP were the key finding in affected
individuals. However, a few cases are documented with
only minimal elevation of this parameter. The degree of
persistent hyperphosphatasia in the reported affected in-
dividuals varies over a wide range between about 1.1 and
17 times the age-adjusted upper limit of the normal
range. The mean elevation of AP is about five to six
times the upper limit. Measurements at different ages of
one individual show marked variability of this value, for
example, from two to seven times the upper limit. There
is no association between the AP activity and the degree
of neurological involvement. Furthermore, there is no
correlation between the mutation class and genes with
the level of elevation of AP.
Growth parameters at birth are usually within the
normal range. Most affected individuals remain in the
normal range, although there is evidence of a skewed
distribution towards the upper centiles and a few
affected individuals become overweight. In contrast,
about 8% of the affected individuals develop postnatal
short stature and fail to thrive. About 28% of affected
individuals develop microcephaly, whereas less than 10%
become macrocephalic. Abnormalities of growth and
head size do not correlate with a specific mutation or
gene within this group of genes.
Involvement of other organ systems varies among the
genetically different groups. PIGV, PIGO, and PGAP2 af-
fected individuals frequently suffer from a variety of dif-
ferent malformations. Anorectal malformations, such as
anal atresia or anal stenosis, are the most frequent
anomalies with almost 30% penetrance in the group of
affected individuals. The second most frequent anomaly
is Hirschsprung disease with a frequency of about 26%
in the same group of affected individuals. Vesicoureteral
or renal malformations occur with a similar frequency;
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Table 1 Summary of clinical findings in patients carrying PIGV, PIGO, PGAP2, PGAP3, PIGW, and PIGY mutations
HPMRS1 PIGV (n = 26,
excluding 2 fetus)
HPMRS2 PIGO
(n = 16)
HPMRS3 PGAP2
(n = 12)
HPMRS4 PGAP3
(n = 26)
HPMRS5 PIGW
(n = 3)
HPMRS6 PIGY
(n = 4)
Hyperphosphatasia 26/26 14/14, ND in 2 6/6, ND in 6 25/26 1/3 4/4
Growth parameters
OFC Normal in 22/26 (microcephaly in
2/26, macrocephaly in 2/26)
Normal in 2/6
(microcephaly in
4, macrocephaly
in 2, ND in 8)
Normal in 5/
12
(microcephaly
in 7)
Normal in 17/26
(microcephaly in 7,
macrocephaly in 2)
Normal in 2
(ND in 1)
Normal in 2/4
(microcephaly
in 2)
Height Normal in 24/26 Normal in 3/5
(short stature in 2,
ND in 11)
Normal in 2/2,
ND in 10
Normal in 25/26
(short stature in 1/
26)
Normal in 2
(ND in 1)
Normal in 2/4
(short stature
in 2/4)
Weight Normal in 24/26 Normal in 4/5
(dystrophy in 1,
ND in 11)
Normal in 2/2,
ND in 10
Normal in 21/26
(overweight in 2/26,
dystrophy in 3/26)
Normal in 2
(ND in 1)
ND
Neurological phenotype
Global
developmental
delay
26/26 16/16 2/2 26/26 3/3 4/4
Motor delay 26/26 16/16 12/12 (mild in
5)
26/26 3/3 4/4
Speech and
language
developmental
delay
26/26 (no speech in 6/10) 16 (no speech in
5/16)
11/12 26/26 (no speech in
20/26)
3/3 4/4
Muscular
hypotonia
18/24, ND in 2 11/11, ND in 5 5/6, ND in 6 23/26 2/2, ND in 1 ND
Seizures 20/26 11/12, ND in 4 8/12 17/26 Autistic traits
1/3
2/4
Behavioral
abnormalities
ND ND ND 21/26 ND 2/4
Other
neurological
abnormalitites
Hearing loss Hearing
impairment (5/16),
thin corpus
callosum
Hearing
impairment
Ataxia (10/26); no
walking in 8/26
- Regression of
acquired skills
(2/4)
HPMRS1 (PIGV) HPMRS2 (PIGO) HPMRS3
(PGAP2)
HPMRS4 (PGAP3) HPMRS5
(PIGW)
HPMRS6
(PIGY)
Malformations
Cleft palate 8/26 4/16 1/12 15/26 - 0/4
Megacolon 8/26 5/16 1/12 0/26 - 0/4
Anorectal
malformations
9/26 3/16 1/12 0/26 - 0/4
Vesicoureteral/
renal malformations
6/10 2/16 ND 0/26 - 1/4
Heart defect 5/26 2/16 2/12 2/26 - 0/4
Facial gestalt
Apparent
hypertelorism
26/26 6/6, ND in 10 1/12 12/13, ND in 13 ND 1/4
Up-slanting
palpebral fissure
26/26 10/11, ND in 5 ND in 12 2/26 ND 0/4
Broad nasal bridge 26/26 5/6, ND in 10 2/12 13/13, ND in 13 1/3 ND in 2 1/4
Broad nasal tip 26/26 5/6, ND in 10 1/12 4/14, ND in 12 ND 1/4
Short nose 26/26 5/6, ND in 10 1/12 14/24, ND in 2 ND ND
Tented upper lip
vermilion
26/26 7/8, ND in 8 2/12 17/24, ND in 21 3/3 ND
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among these are congenital hydronephrosis, megaureter,
and vesicoureteral reflux. Our data revealed a frequency
of heart defects of about 20% in the group of affected in-
dividuals with PIGV, PIGO, and PGAP2 mutations; how-
ever, the type of cardiac abnormality is variable. Only 2
of 26 affected individuals carrying PGAP3 mutations have
variable congenital heart defects. Cleft palate is the malfor-
mation with the highest frequency in the group of affected
individuals with PGAP3 mutations with a prevalence of al-
most 60%, whereas other malformations are rarely ob-
served. Exceptional is a group of ten Egyptian individuals
with the same founder mutation and a high incidence of
structural brain anomalies (thin corpus callosum (8/10),
vermis hypoplasia (4/10), ventriculomegaly (3/10), and
Dandy-Walker malformation (1/10)) [39]. To date these are
the few individuals with a presumably complete loss of
function for this gene (NM_033419.3:c.402dupC, p.Met1
35Hisfs*28; c.817_820 delGACT, p.Asp273Serfs*37).
Malformations had not been observed in the single
reported affected individual with PIGW mutations [3].
Apart from dilation of renal collecting systems,
affected individuals with PIGY mutations presented
with a new spectrum of organ involvement such as
cataracts, rhizomelic shortness of limbs, contractures
and hip dysplasia [6].
All affected individuals with PIGV and PIGO
mutations had a variable degree of distal hand anomal-
ies, namely brachytelephalangy. They showed hypoplas-
tic finger nails as well as hypoplastic distal phalanges in
hand X-rays. Often, they displayed broad and short distal
phalanges of the thumbs and halluces, including short
and broad corresponding nails of the affected digits.
Brachytelephalangy is not present in any of the affected
individuals with PGAP3, PGAP2, and PIGW mutations,
respectively, although one-third showed broad nails
without radiological abnormalities in the available X-
rays. One of four affected individuals with PIGY
mutations showed brachytelephalangy.
A multidisciplinary approach is required to manage the
GPIBDs described in this section, as the clinical variability
is broad. It is recommended that all affected individuals
have at least one baseline renal ultrasound investigation as
Table 1 Summary of clinical findings in patients carrying PIGV, PIGO, PGAP2, PGAP3, PIGW, and PIGY mutations (Continued)
HPMRS1 PIGV (n = 26,
excluding 2 fetus)
HPMRS2 PIGO
(n = 16)
HPMRS3 PGAP2
(n = 12)
HPMRS4 PGAP3
(n = 26)
HPMRS5 PIGW
(n = 3)
HPMRS6 PIGY
(n = 4)
Large, fleshy ear
lobes
- 1/16 18/24, ND in 21 ND 4/4
Brachytelephalangy 26/26 10/10, ND in 6 0/12 (broad
nails in 1/12)
0/26 (broad nails in
6/26)
- 1/4
Further anomalies
(rare)
Gastroesophageal reflux, optic
atrophy bilateral, scoliosis, hip
subluxation (right), thin corpus
callosum, gingiva hyperplasia
Coronal synostosis,
keratoderma,
micrognathia,
auricular
malformations
Thin corpus callosum
(9/26),
ventriculomegaly (3/
26), vermis
hypoplasia (4/26)
Inguinal
hernia (1/3)
Cataracts (2/
4)
Rhizomelic
shortness of
limbs (2/4)
Contractures
(2/4)
Hip dysplasia
(2/4)
Published cases Rabe et al. 1991 [33] Krawitz et al. 2012
[7]
Hansen et al.
2013 [4]
Howard et al. 2014
[5]
Chiyonobu
et al. 2014 [3]
Ilkovski et al.
2015 [6]
Marcelis et al. 2007 [34] Kuki et al. 2013
[36]
Krawitz et al.
2013 [8]
Knaus et al. 2016
[19]
Hogrebe
et al. 2016
[20]
Krawitz et al. 2010 [9] and Horn
et al. 2010 [60]
Nakamura et al.
2014 [16]
Jezela-Stanek
et al. 2016
[18]
Pagnamenta et al.
2017 [40]
Horn et al. 2011 [28] Xue et al. 2016
[31]
Naseer et al.
2016 [38]
Nampoothiri et al.
2017 [41]
Thompson et al. 2012 [29] Morren et al. 2017
[35]
Abdel-Hamid et al.
2017 [39]
Horn et al. 2014 [30] Zehavi et al. 2017
[17]
2 unpublished cases
Xue et al. 2016 [31] Tanigawa 2017
[37]
Reynolds et al. 2017 [32]
6 unpublished cases
ND not documented; OFC occipitofrontal head circumference
Knaus et al. Genome Medicine  (2018) 10:3 Page 5 of 13
well as echocardiography to rule out any obvious malfor-
mations. In case of chronic obstipation, Hirschsprung
disease, as well as anal anomalies, should be excluded.
Hearing evaluation is recommended in all affected individ-
uals. Individuals with behavioral problems may benefit
from a review by a clinical psychologist. Regular develop-
mental assessments and EEG investigations are required
to ensure that affected individuals get optimal support.
The tendency towards epilepsies has been reported to
decrease in some affected individuals with age and if the
affected individual and physician agree to a trial discon-
tinuation of therapy, medications could be tapered.
Clinical overview of MCAHS
MCAHS comprises a group of genetically different dis-
orders characterized by early onset forms of different
types of epilepsies with poor prognosis, missing or min-
imal psychomotor development, and often, early death
(Table 2). The phenotypic series include individuals with
PIGA (MIM 300868) [10, 13–15, 42–46], PIGN (MIM
614080) [12, 18, 47–53], and PIGT (MIM 615398) [11,
40, 54–57] mutations.
Neonatal muscular hypotonia is often present. The
variable congenital anomalies affect the renal/vesicouret-
eral, cardiac, and gastrointestinal systems. Brain imaging
showed variable abnormalities, for example, thin corpus
callosum, cerebellar atrophy/hypoplasia, cerebral atro-
phy, and delayed myelination, but also normal findings
in other affected individuals. There is overlap with the
spectrum of malformations seen in HPMRS. Exceptions
are megacolon, which is only reported in individuals
with PIGV, PIGO, and PGAP2 mutations, and diaphrag-
matic defects, which are only documented in three fe-
tuses with PIGN mutations [51]. In addition, joint
contractures and hyperreflexia are documented in some
individuals with PIGA and PIGN mutations [10, 13–15,
Table 2 Comparison of phenotypic data and biomarkers in different types of MCAHS
GPIBDs: affected gene (individuals) MCAHS2 PIGA (n = 26) MCAHS1 PIGN (n = 20, including three fetuses) MCAHS3 PIGT (n = 14)
Hyperphosphatasia +/− +/− +
Seizures with early onset + + +
Early death +/− +/− −
Profound ID + + +
Neonatal muscular hypotonia +/− +/− +
Macrocephaly or macrosomia +/− +/− +/−
Variable brain anomalies +/− + +
Hyperreflexia/contractures +/− +/− ND
Variable facial anomalies +/− +/− +/−
Renal/vesicoureteral anomalies +/− +/− +/−
Gastrointestinal anomalies +/− +/− ND
Cardiovascular abnormalities ND +/− ND
Cleft palate + +/− −
Diaphragmatic defect − +/− −
Short distal phalanges − +/− −
Elevated alkaline phosphatase (AP) +/− (5/23 elevated AP) − Decreased AP
Abnormal flow cytometry results +/ND +/ND +/ND
Published cases Johnston et al. 2012 [10] Maydan et al. 2011 [12] Kvarnung 2013 [11]
van der Crabben et al. 2014 [15] Brady et al. 2014 [48] Nakashima 2014 [54]
Swoboda et al. 2014 [43] Ohba et al. 2014 [47] Lam 2015 [55]
Kato et al. 2014 [14] Couser et al. 2015 [49] Skauli 2015 [56]
Belet et al. 2014 [42] Fleming et al. 2015 [52] Kohashi 2017 [57]
Tarailo-Graovac et al. 2015 [44] Khayat et al. 2015 [53] Pagnamenta 2017 [40]
Joshi et al. 2016 [46] Nakagawa et al. 2016 [50] 3 unpublished cases
Fauth et al. 2016 [13] Jezela-Stanek et al. 2016 [18]
Kim et al. 2016 [45] McInerney-Leo et al. 2016 [51]
9 unpublished cases
ND not documented
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42–46]. Macrocephaly or macrosomia occur in some of
these individuals, whereas microcephaly occurs in others.
No distinct facial phenotype is recognizable in comparison
within and between the genetically different groups of
MCAHS.
Interestingly, 5 out of 23 individuals with PIGA muta-
tions had elevated AP measurements, whereas only one
individual with PIGN mutations was reported with border-
line high AP activity [52]. In contrast, some of the individ-
uals with PIGT mutations showed decreased AP [11, 54].
HPMRS and MCAHS display an overlapping clinical
spectrum but MCAHS has a considerably worse prognosis
due to early onset and often intractable seizures as well as
early death in the majority of affected individuals. However,
facial dysmorphisms do not appear to be characteristic in
the different types of MCAHS in contrast to HPMRS. Im-
portantly, elevation of AP and reduced surface levels of
GPI-linked substrates are not restricted to HPMRS.
Flow cytometry
Flow cytometry analysis of blood
Flow cytometry was performed on granulocytes ex-
tracted from peripheral blood draws that were sampled
in BCT CytoChex tubes (Streck, NE, USA), shipped, and
analyzed in less than 72 h. Whole blood (50 μl) was
mixed with 20 μl of an antibody panel:
1. 4 μl CD55-PE (BD #555694), 4 μl CD59-FITC (BD
#555763), 2 μl CD45-PacBlue (Beckman Coulter,
clone J.33), and 10 μl FACS buffer.
2. 2 μl CD16-PE (Beckman Coulter, clone 3G8), 4 μl
FLAER-AF488 (FL2S-C; Burlington, Canada,), 2 μl
CD45-PacBlue (Beckman Coulter, clone J.33), and
12 μl FACS buffer.
3. 2 μl CD24-APC (MiltenyiBiotec Clone REA832),
2 μl CD45-PacBlue (Beckman Coulter, clone J.33),
and 16 μl FACS buffer.
The staining was incubated for 30 min at room
temperature followed by an incubation with 500 μl red
blood cell lysis buffer for 10 min. Debris was removed by
discarding the supernatant after centrifugation and the cell
pellet was washed twice with 200 μl and resuspended in
100 μl FACS buffer for flow cytometry analysis on a
MACSQuant VYB (MiltenyiBiotec, Bergisch Gladbach,
Germany).
Gating for living cells was based on forward and side
scatter (FSC-A vs. SSC-A). Single cells were gated on a
diagonal (FSC-A vs. FSC-H). Granulocytes were identi-
fied as granular (SSC-A high) and CD45-positive cells.
The reduction of GPI-AP expression was assessed by
the ratio of the median fluorescence intensity (MFI) of
the patient to the MFI of a shipped healthy control.
Heterozygous carriers of pathogenic mutations (parents)
were used as controls when unrelated healthy controls
were not available. It is noteworthy that differences in
GPI-AP expression were subtle in healthy parents
compared to unrelated controls. To compare marker
reduction of published and unpublished cases only
FLAER and CD16 were used.
Flow cytometric analysis of fibroblast cells
Fibroblasts derived from skin biopsies of patients, par-
ents, and healthy control individuals were cultured in
DMEM supplemented with 10% FCS, 1% ultraglutamine,
1% penicillin/streptomycin. For flow cytometry analysis
confluently grown cells were washed twice with PBS
(-Ca2+, -Mg2+); the cells were gently detached from the
coulter dish with Trypsin-EDTA (0.01%). The single cell
suspension was washed with FACS buffer, counted, di-
luted (100.000 cells/stain), and centrifuged, after which
the supernatant was discarded and the cell pellet was re-
suspended in the following antibody mix.
1. 4 μl CD55-PE (BD #555694), 4 μl CD59-FITC (BD
#555763), and 12 μl FACS buffer.
2. 4 μl CD73-PE (BD#550257), 4 μl FLAER-AF488
(Cedarlane, FL2S-C), and 12 μl FACS buffer.
The staining was incubated for 30 min at room
temperature followed by two washing steps with 200 μl
FACS buffer. For flow cytometry analysis on a MACS-
Quant VYB the cells were resuspended in 100 μl FACS
buffer.
Reduction of GPI-AP expression was calculated as a ra-
tio between the median fluorescence intensity (MFI) of
the patient against the mean of MFIs from healthy parents
and a healthy unrelated control. It is noteworthy that het-
erozygous carriers of pathogenic mutations (parents) and
unrelated healthy controls had only subtle differences in
GPI-AP expression.
Computer-assisted phenotype comparison
Facial images of all individuals with a molecularly
confirmed GPIBD were assessed with the Face2Gene
Research Application (FDNA Inc., Boston MA, USA).
This software tool set allows the phenotypic compari-
son of user-defined cohorts with ten or more individ-
uals. The classification model of Face2Gene Research
uses a neural network architecture that consists of
ten convolutional layers, each but the last followed by
batch normalization. The original collections are split
into training and test sets for cross-validation and
mean accuracies for the classification process are
computed. The result of a single experiment is a con-
fusion matrix that describes the performance of the
Knaus et al. Genome Medicine  (2018) 10:3 Page 7 of 13
classification process. As cohort size is a known con-
founder, we randomly sampled all cohorts down to the
same size (n = 10) and computed the mean true positive
and error rates as well as the standard deviation from ten
iterations [58]. The scripts for the simulations are available
on request and can be used to reproduce the results.
Results
Flow cytometric assessment of GPIBDs
We acquired fibroblast cultures of affected individuals to
perform measurements under the same experimental
conditions repeatedly. The marker FLAER, which binds
to the GPI anchor directly, as well as the GPI-APs
CD55, CD59, and CD73, which show high expression
levels on fibroblasts, were assessed (Fig. 1). We hypothe-
sized that measuring cell surface levels of GPI-linked
substrates directly by flow cytometry might be more
suitable to quantify the severity of a GPIBD or to predict
the affected gene. No significant differences between pa-
tients with MCAHS were observed compared to patients
with HPMRS (Fig. 1a). Furthermore, the cell surface
levels of CD55 and CD59 were on average lower in cells
that were derived from individuals with mutations in
PGAP3 compared to individuals with mutations in PIGV
(Additional file 1: Table S1), although this did not
correspond to a higher prevalence of seizures or a more
severe developmental delay. CD55 and CD59 are of par-
ticular interest as they protect cells from an attack on
the activated complement system and the membrane
attack complex that has also been shown to be involved
in the pathogenesis of seizures [59].
The samples with pathogenic mutations in PIGV are
noteworthy as they are derived from individuals that
differ considerably in the severity of their phenotype:
14-0585 was born with multiple malformations and
his seizures are resistant to treatment, whereas the
other three individuals, A2, A3, and P1, are consid-
ered to be moderately affected. The flow cytometric
profiles, however, do not show marked differences.
Furthermore, the cell surface levels of CD55 and
CD59 were on average lower in cells that were
derived from individuals with mutations in PGAP3.
While the reproducibility of the flow cytometric
data on fibroblasts is attractive, the small size of the
sample set is clearly a disadvantage in the assessment
of potential differences between the phenotypic sub-
groups of GPIBDs. Most flow cytometric analyses
have been performed on granulocytes of affected indi-
viduals with the markers CD16 and FLAER and we
added a comparison of the relative median fluorescent
intensities (rMFI) for a total of 39 individuals of the
phenotypic series MCAHS and HPMRS (Additional
file 1: Table S2). Although individuals of the MCAHS
spectrum are usually more severely affected than indi-
viduals of the HPMRS spectrum, we did not observe
any significant differences for the tested markers
(Fig. 1b). Thus, no significant correlation between
FACS profiles of the two phenotypic series was found.
Comparison of the facial gestalt of GPIBDs
The craniofacial characteristics of many Mendelian dis-
orders are highly informative for clinical geneticists and
have also been used to delineate gene-specific pheno-
types of several GPIBDs [3–5, 10, 12, 19, 28–30, 32, 39,
40, 43, 44, 60, 61]. However, our medical terminology is
often not capable of describing subtle differences in the
facial gestalt. Therefore, computer-assisted analysis of
the gestalt has recently received much attention in syn-
dromology and several groups have shown that the clin-
ical face phenotype space (CFPS) can also be exploited
a b
Fig. 1 Flow cytometric profiling for GPIBDs. Cell surface levels of FLAER and tissue-specific GPI-anchored proteins were assessed on fibroblasts (a) as
well as on granulocytes (b) of individuals affected by GPIBDs. The relative expression was grouped for GPIBDs of the same phenotypic series, MCAHS
(PIGA, PIGN, PIGT) and HPMRS (PGAP3, PIGV, PIGO, PIGW), but showed no significant differences (significance was tested with Wilcoxon-Mann-Whitney
test; the p value was corrected for sample size (Bonferoni))
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by machine learning approaches [62]. If a recognizable
gestalt exists, a classifier for facial patterns can be
trained to infer likely differential diagnoses. Conversely,
if photos of affected individuals with disease-causing
mutations in different genes of a pathway form separate
clusters, it indicates that the gestalt is distinguishable to
a certain extent. FDNA’s recently launched RESEARCH
application is a deep learning tool for exactly this purpose
(https://app.face2gene.com/research): a classification model
is generated on two or more collections of frontal images
and the performance is reported as a confusion matrix. If
true positive rates for the single gene–phenotypes are
achieved that are significantly better than for a random as-
signment of photos to cohorts, there is some phenotypic
substructure and the null hypothesis of perfect
heterogeneity may be rejected.
We used the RESEARCH app of the Face2Gene suite
to evaluate a classifier for the five most prevalent
GPIBDs, PIGA (n = 20), PIGN (n = 11), PIGT (n = 12),
PIGV (n = 25), and PGAP3 (n = 23). Our original sample
set thus consists of frontal facial photos of 91 individuals
with a molecularly confirmed diagnosis of HPMRS or
MCAHS, including cases that have been previously pub-
lished [5, 9–11, 13–15, 19, 28–30, 32–34, 39, 43, 47, 49,
50, 52–56, 60, 63]. The mean accuracy that was achieved
on this original sample set was 52.2%, which is signifi-
cantly better than random. In order to compare the per-
formance for the single gene classes we had to exclude
confounding effects from unbalanced cohort sizes and
sampled the cohorts down to the same size of n = 10.
Although this decreases the overall performance, the
mean accuracy of 45.8% is still significantly better than
the 20% that would be achieved by chance in a five-class
problem for evenly sized cohorts (Fig. 2). Furthermore,
for every single gene–phenotype, the true positive rate
(TPR) was better than randomly expected, with PIGV
achieving the highest value (59%).
Interestingly, we observed the highest false negative
rate in the confusion matrix for PGAP3 (HPMRS4): on
average 32% of these cases are erroneously classified as
PIGV (HPMRS1) cases. This finding is in good agree-
ment with the phenotypic delineation from syndromolo-
gists that grouped these to genes in the same subclass. A
cluster analysis of the confusion matrix actually repro-
duces the two phenotypic series as shown by the
dendrogram in Fig. 2.
While the confusion matrix on the entire sample set
can be used to decide whether there are gene-specific
substructures in the GPI pathway, pairwise comparisons
are better suited to derive phenotypic differences
between genes even inside a phenotypic series. We
therefore evaluated the area under the receiver operating
characteristics curve (AUC) and found the correct gene
prediction more often than randomly expected,
including PIGV versus PGAP3 (Additional file 1: Figure
S3). The differences in pair-wise comparison between
PIGV and PGAP3 could be confounded by the large
number of Egyptian cases in the PGAP3 cohort [39], the
effect of which we could not further analyze due to the
limited set of patient photos.
Discussion
The identification of multiple affected individuals with
GPIBDs has enabled the analysis of genotype–phenotype
relationships for the molecular pathway of GPI anchor
synthesis. Besides a developmental delay and seizures,
which are common findings in most affected individuals
with a GPIBD, the clinical variability and the variation in
expressivity is wide. So far, recognizable gene-specific
phenotypes seem to be accepted for PIGL and are
discussed for PIGM [64, 65]. For other GPIBDs the
phenotypic series HPMRS and MCAHS have been used
to subgroup the pathway and the activity of AP in serum
was the main classification criterion. However, these dis-
ease entities are increasingly cumbersome as some cases
are now known to not follow this oversimplified rule.
We therefore compared GPIBDs based on deep phe-
notyping data and flow cytometric profiles of GPI-APs.
Among the 16 genes of the GPI pathway with reports of
affected individuals, mutations in PIGA, PIGN, PIGT,
PIGV, and PGAP3 were most numerous and these
GPIBDs were also suitable for automated image analysis.
A systematic evaluation of the phenotypic features
showed that certain malformations occur with a higher
frequency in specific GPIBDs. To date, megacolon has
only been found to be associated with PIGV, PIGO, and
PGAP2 mutations. Diaphragmatic defects have only been
documented in affected individuals with PIGN muta-
tions. Only in individuals with PGAP3 mutations are be-
havioral problems, especially sleep disturbances and
autistic features, present, in about 90%. In addition,
ataxia and unsteady gait are also frequently documented
in this group but not in the others. An accurate classifi-
cation that is merely based on clinical symptoms is,
however, not possible due to their high variability. Also,
flow cytometric analysis of GPI marker expression was
not indicative for the gene defect and did not correlate
with the severity of the phenotype. Of note, however, an
assessment of the GPI-AP expression levels seems more
sensitive in fibroblasts than in blood cells [24]. This
might also be related to the trafficking pathways of
GPI-APs through endoplasmic reticulum and Golgi that
differ for cell types and substrates [66, 67].
The overlapping clinical spectrum of both HPMRS and
MCAHS, the findings of elevated AP, and the reduced sur-
face levels of GPI-linked proteins in some of the MCAHS
cases favor a common classification as GPIBDs.
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In light of the high variability and expressivity of the
clinical findings and the weak genotype–phenotype correl-
ation, the most surprising finding of our study was the
high discriminatory power that facial recognition technol-
ogy achieved. In spite of the similarity of the pathophysi-
ology, differences in the gestalt are still perceptible. This
illustrates the remarkable information content of human
faces and advocates for the power of computer-assisted
syndromology in the definition of disease entities.
Automated image analysis of syndromic disorders is a
comparably new field of research and the approach that
we used requires photos of at least ten individuals per
cohort. However, it is currently not known if there is a
minimum number of cases that is required to assess
whether a gene–phenotype is recognizable. Furthermore,
for every rare disorder with a characteristic gestalt there is
possibly a maximum value for the recognizability. So far,
the approximation of this upper limit has not systematic-
ally been studied depending on the number of individuals
that were used in the training process and should defin-
itely be a focus for future research.
Conclusions
A gene-centered classification of GPIBDs is recommended
due to the overlapping clinical spectrum of both HPMRS
and MCAHS in the majority of affected individuals. Measur-
ing AP serum activity and cell surface levels of GPI-linked
markers is still regarded as an imperative in the diagnostic
work-up of GPIBDs, especially when dealing with mutations
that have not been reported previously. In addition, next-
generation phenotyping tools can add another layer of infor-
mation in the interpretation of novel mutations in the GPI
anchor pathway, particularly if the flow cytometric data are
inconclusive.
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